肺腺癌转化小细胞癌的多线治疗分析及文献复习

Analysis of multiline therapy for small cell lung cancer transformed from lung adenocarcinoma and review of the literature

目的探究肺腺癌转化小细胞肺癌(small cell lung cancer,SCLC)的多线治疗方案效果并进行相关文献复习讨论。方法结合肺腺癌经抗表皮生长因子受体酪氨酸激酶抑制剂(tyrosine kinase inhibitor against epidermal growth factor receptor,EGFR-TKIs)治疗后转化SCLC的临床实例,对转化性SCLC的诊断过程、多线治疗方案进行分析,并对治疗效果进行影像学评价;同时结合相关文献资料进行讨论。结果血清学肿瘤标志物对肺腺癌EGFR-TKI治疗后转化SCLC的诊断有提示意义,病理仍为其诊断金标准;SCLC的多线治疗方案对于转化性小细胞肺癌有一定效果。结论肺腺癌EGFR-TKIs治疗后转化SCLC总体预后不佳,须尽早进行诊断、治疗,并及时进行影像学评效,迅速做出治疗调整。

Objective To investigate the effect of multi line therapy for lung adenocarcinoma transformed into small cell lung cancer(SCLC),and review and discuss the related literature.Methods Combined with the clinical examples of lung adenocarcinoma transformed SCLC after treatment with anti epidermal growth factor receptor tyrosine kinase inhibitors(EGFR TKIs),the diagnostic process and multi line treatment plan of transformed SCLC were analyzed,and the therapeutic effect was evaluated by imaging.At the same time,it was reviewed and discussed in combination with relevant literature.Results Serological tumor markers were significant for the diagnosis of transformed SCLC after EGFR-TKI treatment of lung adenocarcinoma,and pathology was still the gold standard for its diagnosis.The multiline therapy of SCLC has certain effect on transformed small cell lung cancer.Conclusion The overall prognosis of lung adenocarcinoma transformed into SCLC after EGFR TKIs treatment is poor,so it is necessary to diagnose and treat it as early as possible,evaluate the effect of imaging in time,and make treatment adjustment quickly.